ST. LOUIS, Jan. 3, 2013 (GLOBE NEWSWIRE) -- ISTO Technologies, Inc., a privately-held orthobiologics company, announced today that it is participating in OneMedPlace's 6th Annual OneMedForum SF 2013 conference to be held at the Sir Francis Drake Hotel in San Francisco, CA from January 7th through January 9th. Mitchell Seyedin, Ph.D., President and Chief Executive Officer, and Scott Gill, Chief Financial Officer, will be presenting on Tuesday, January 8th, 2013 at 8:40 AM (PT) in the Windsor Room. The conference is a gathering of leading investors and management of some of the most promising emerging life science companies in Europe and North America. The three-day forum will feature over 100 emerging growth companies showcasing the most innovative technology in life sciences.
ISTO's proprietary cell-based orthobiologic platform harnesses the regenerative capacity of juvenile cartilage cells to create products designed to repair and restore function to damaged cartilage tissue. The company believes that the two clinical-stage products currently comprising ISTO's cell-based program, DeNovo® ET and NuQu®, potentially represent breakthrough technologies addressing two significant unmet medical needs: damaged knee cartilage and discogenic back pain. These products utilize juvenile chondrocytes that have a proven superior capacity for cartilage regeneration compared to adult cells.
In addition to ISTO's cell-based cartilage programs, the company is currently manufacturing and marketing InQu®, a bone graft extender and substitute. InQu combines integrated hyaluronic acid and a synthetic polymer for better handling and biology. The primary target market for the product is spinal fusion applications. InQu has been used in over 20,000 surgeries at U.S. hospitals to date.
ISTO is a privately-held orthobiologics company dedicated to improving patient quality of life through the development of proprietary products for spinal therapies and sport medicine applications. ISTO's products are intended for the repair and regeneration of damaged or injured cartilage and bone. For additional information on ISTO, please visit our website at www.istotech.com.
CONTACT: ISTO Technologies, Inc. Scott Gill Chief Financial Officer (314) 995-6049 The Ruth Group Nick Laudico (investors) (646) 536-7030 email@example.com Kimberly Muscara (media) (646) 536-7011 firstname.lastname@example.orgSource: ISTO